← Leaderboards
Elaine R. Peskind
Va Puget Sound Healthcare System
$23,978,860
Attributed
$25,640,494
Total exposure
14
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,640,494 · 9
VA$0 · 5
By mechanism
P50$8,665,893 · 3
T32$5,876,495 · 1
R01$4,191,289 · 3
RF1$3,859,922 · 1
U19$3,046,895 · 1
I01$0 · 5
Top collaborators
- Brian C. Kraemer5 shared
- Eric C Petrie4 shared
Most similar at Va Puget Sound Healthcare System
Same institution · by research overlap
- Charles W. Wilkinson$0
- Steven E Kahn$45,062,959
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposCerebrospinal FluidS DiseaseDementiaNerve DegenerationBrainVeteransBiological MarkersSymptomsNeurodegenerative DementiaResponseNeuroimagingClinical ResearchLiquid SubstanceBehavioralPost-Traumatic Stress DisordersDiagnosisNeuropathologyElderlyImpaired CognitionAutopsyAfghanistanIraqNeurologic
Grant awards (67)
Defining the Role of Post-TBI Sleep Disruption in the Development of CTE and Alzheimer's Disease-Related Neuropathology$1,253,356
R01 · FY2025 · NS · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$835,492
T32 · FY2025 · AG · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$84,354
T32 · FY2025 · AG · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$850,926
T32 · FY2024 · AG · contact PI
Mild TBI and Biomarkers of Neurodegeneration$0
I01 · FY2024 · VA · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$786,648
T32 · FY2023 · AG · contact PI
Mild TBI and Biomarkers of Neurodegeneration$0
I01 · FY2023 · VA · contact PI
Defining the Role of Post-TBI Sleep Disruption in the Development of CTE and Alzheimer's Disease-Related Neuropathology$3,859,922
RF1 · FY2022 · NS · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$765,849
T32 · FY2022 · AG · contact PI
Mild TBI and Biomarkers of Neurodegeneration$0
I01 · FY2021 · VA · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$519,764
T32 · FY2020 · AG · contact PI
Mild TBI and Biomarkers of Neurodegeneration$0
I01 · FY2020 · VA · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$695,035
T32 · FY2019 · AG · contact PI
Mild TBI and Biomarkers of Neurodegeneration$0
I01 · FY2019 · VA · contact PI
Clinical Core$463,902
P50 · FY2018 · AG · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$343,190
T32 · FY2018 · AG · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$313,726
T32 · FY2018 · AG · contact PI
Mild TBI and Biomarkers of Neurodegeneration$0
I01 · FY2018 · VA · contact PI
PRAZOSIN FOR AGITATION IN ALZHEIMER'S DISEASE$478,747
U19 · FY2017 · AG · contact PI
Clinical Core$438,665
P50 · FY2017 · AG · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$332,511
T32 · FY2017 · AG · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$7,508
T32 · FY2017 · AG · contact PI
Mild TBI and Biomarkers of Neurodegeneration$0
I01 · FY2017 · VA · contact PI
Multimodal Biological Assessment of Gulf War Illness$0
I01 · FY2017 · VA · contact PI
Simvastatin: Proof-of-Concept for Prevention of Neurodegeneration in Mild TBI$0
I01 · FY2017 · VA · contact PI
PRAZOSIN FOR AGITATION IN ALZHEIMER'S DISEASE$1,376,601
U19 · FY2016 · AG · contact PI
Clinical Core$438,410
P50 · FY2016 · AG · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$341,492
T32 · FY2016 · AG · contact PI
Mild TBI and Biomarkers of Neurodegeneration$0
I01 · FY2016 · VA · contact PI
Multimodal Biological Assessment of Gulf War Illness$0
I01 · FY2016 · VA · contact PI
PRAZOSIN FOR AGITATION IN ALZHEIMER'S DISEASE$1,191,547
U19 · FY2015 · AG · contact PI
Clinical Core$438,285
P50 · FY2015 · AG · contact PI
Multimodal Biological Assessment of Gulf War Illness$0
I01 · FY2015 · VA · contact PI
Simvastatin: Proof-of-Concept for Prevention of Neurodegeneration in Mild TBI$0
I01 · FY2015 · VA · contact PI
Mild TBI and Biomarkers of Neurodegeneration$0
I01 · FY2015 · VA · contact PI
Simvastatin: Proof-of-Concept for Prevention of Neurodegeneration in Mild TBI$0
I01 · FY2015 · VA · contact PI
Simvastatin: Proof-of-Concept for Prevention of Neurodegeneration in Mild TBI$0
I01 · FY2015 · VA · contact PI
CLINICAL CORE$710,220
P50 · FY2014 · AG · contact PI
Mild TBI and Biomarkers of Neurodegeneration$0
I01 · FY2014 · VA · contact PI
Mild TBI and Biomarkers of Neurodegeneration$0
I01 · FY2014 · VA · contact PI
Multimodal Biological Assessment of Gulf War Illness$0
I01 · FY2014 · VA · contact PI
Mild TBI and Biomarkers of Neurodegeneration$0
I01 · FY2014 · VA · contact PI
CLINICAL CORE$664,282
P50 · FY2013 · AG · contact PI
CLINICAL CORE$710,218
P50 · FY2012 · AG · contact PI
CLINICAL CORE$727,766
P50 · FY2011 · AG · contact PI
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease$476,774
R01 · FY2011 · AG · contact PI
Mild TBI and Biomarkers of Neurodegeneration$0
I01 · FY2011 · VA · contact PI
CLINICAL CORE$717,388
P50 · FY2010 · AG · contact PI
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease$493,474
R01 · FY2010 · AG · contact PI
CORE--CLINICAL$738,086
P50 · FY2009 · AG · contact PI
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease$494,731
R01 · FY2009 · AG · contact PI
CORE--CLINICAL$719,017
P50 · FY2008 · AG · contact PI
CORE--CLINICAL$714,883
P50 · FY2007 · AG · contact PI
CORE--CLINICAL$487,801
P50 · FY2006 · AG · contact PI
CORE--CLINICAL$473,801
P50 · FY2005 · AG
ALZHEIMER'S IN LONG TERM PROPRANOLOL FOR AGITATION$309,800
R01 · FY2003 · AG
ALZHEIMER'S IN LONG TERM PROPRANOLOL FOR AGITATION$378,032
R01 · FY2002 · AG
CORE--CLINICAL$0
P50 · FY2002 · AG
CORE--CLINICAL$0
P50 · FY2002 · AG
ALZHEIMER'S IN LONG TERM PROPRANOLOL FOR AGITATION$311,100
R01 · FY2001 · AG
ALZHEIMER'S IN LONG TERM PROPRANOLOL FOR AGITATION$159,022
R01 · FY2001 · AG
CORE--CLINICAL$4,545
P50 · FY2001 · AG
CORE--CLINICAL$0
P50 · FY2001 · AG
ALZHEIMER'S IN LONG TERM PROPRANOLOL FOR AGITATION$315,000
R01 · FY2000 · AG
CORE--CLINICAL$209,534
P50 · FY2000 · AG
CORE--CLINICAL$4,545
P50 · FY2000 · AG
CORE--CLINICAL$4,545
P50 · FY2000 · AG